Five Jan Aushadhi centres set up at Mahakumbh Mela

IMT News Desk
IMT News Desk
· 2 min read

The centres aim to ensure the availability and awareness of affordable and quality medicines to the pilgrims

Five Jan Aushadhi centres have been set up in Mahakumbh Nagar, with one located in Kalagram, under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) of the Government of India. These centres will remain operational throughout the Mahakumbh Mela. These centres aim to ensure the availability and awareness of affordable and quality medicines to the pilgrims.

Ravi Dadhich, CEO, Pharmaceutical and Medical Devices Bureau of India (PMBI), Department of Pharmaceuticals, Government of India, reviewed the Jan Aushadhi Stall and other Jan Aushadhi centres in Prayagraj. He said, “Purchasing medicines from Jan Aushadhi centres save the public 50 to 90 per cent on costs.”

During his visit, he interacted with visitors and centre operators to discuss the utility and benefits of the PMBJP.

The CEO further shared that there are 2,633 Jan Aushadhi centres operating in Uttar Pradesh, with 62 centres functioning in Prayagraj. Across the country, more than 15,000 centres have been opened under the Jan Aushadhi Scheme, with a target of opening 25,000 centres inspired by the vision of Prime Minister Narendra Modi. This year, the target for selling medicines through these centres is Rs 2,000 crores, of which over Rs. 1,500 crores has already been achieved.

He explained the process for Mahakumbh devotees to find the nearest Jan Aushadhi centre through a pin-code-based system and informed them about the availability of affordable medicines. During the event, Dadhich also answered questions from media representatives and expressed gratitude to the media for supporting the Jan Aushadhi Scheme.

PIB

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk